( 12 ) United States Patent
Total Page:16
File Type:pdf, Size:1020Kb
US010293012B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 293 ,012 B2 Langland et al. (45 ) Date of Patent: May 21, 2019 ( 54 ) METHODS OF USING EXTRACTS OF OTHER PUBLICATIONS MELISSA OFFICINALIS AGAINST FILOVIRUSES Chattopadhyay, et al. , Evidence - Based Validation of Herbal Medi cine , Ch . 8 : 175 . ( Year : 2015 ) . * Arndt, W . et al ., “ In Vitro Characterization of a Nineteenth - Century ( 71 ) Applicants : Jeffrey Langland , Chandler, AZ (US ) ; Therapy for Smallpox ” , PLoS One, Mar. 2012 , 7 ( 3 ) , article ID Bertram Jacobs, Tempe , AZ (US ) ; e23610 , 9 pages . Karen Denzler , Phoenix , AZ (US ) Astani , A . et al. , “ Melissa officinalis Extract Inhibits Attachment of Herpes Simplex Virus in vitro ” , Chemotherapy, 2012 (published (72 ) Inventors : Jeffrey Langland , Chandler , AZ (US ) ; online Feb . 2012 ) , 58 , pp . 70 - 77 . Chattopadhyay, D . et al ., “ Ethnomedicines and ethnomedicinal Bertram Jacobs, Tempe , AZ (US ) ; phytophores against herpesviruses” , Biotechnology Annual Review , Karen Denzler , Phoenix , AZ (US ) 2008 (available online Jul. 2008 ) , 14 , pp . 297 - 348 . Cheng, C . et al. , “ Recent Advances in the Discovery of Novel ( 73 ) Assignee : Arizona Board of Regents on behalf Anti -Herpetic Agents from Chinese Herbal Medicines ” , Current of Arizona State University , Scotsdale , Organic Chemistry, 2010 , 14 ( 16 ), pp . 1714 - 1726 . AZ (US ) Downing, A . , “ Inter and intra - specific differences in medicinal plant use for the treatment of type II diabetes symptoms by the Cree Elders of Eeyou Istchee ( QC ) ” , University of Montreal , Papyrus ( * ) Notice : Subject to any disclaimer , the term of this Institutional Repository , Master ' s Thesis , 2010 , 117 pages . patent is extended or adjusted under 35 Harris , C . et al ., " Characterizing the cytoprotective activity of U . S . C . 154 (b ) by 0 days . Sarracenia purpurea L ., a medicinal plant that inhibits glucotoxic ity in PC12 cells ” , BMC Complementary and Alternative Medicine , ( 21 ) Appl. No. : 15 /970 ,222 Dec 2012 , 245 , 10 pages , https : // doi. org / 10 . 1186 / 1472 -6882 - 12 245 . (22 ) Filed : May 3 , 2018 Krauze - Baranowska , A . et al. , “ HPLC of flavanones and chalcones in different species and clones of Sali ” , Acta Poloniae Pharmaceutica , Prior Publication Data Jan . 2013 , 70 ( 1 ) , pp . 27 - 34 . (65 ) Patent Cooperation Treaty , International Searching Authority , Inter US 2018 /0318373 A1 Nov . 8 , 2018 national Preliminary Report on Patentability and Written Opinion for PCT/ US2013 /071332 , 12 pages , report dated May 26 , 2015 , opinion dated Apr . 30 , 2014 . Patent Cooperation Treaty , International Searching Authority, Inter Related U . S . Application Data national Search Report for PCT/ US2013 / 071332, 6 pages , dated (60 ) Provisional application No . 62 /501 , 446 , filed on May Apr. 30 , 2014 . 4 , 2017 Patent Cooperation Treaty , International Searching Authority , Inter national Search Report for PCT/ US2018 / 031538 , 4 pages , dated ( 51) Int. Ci. Sep . 17 , 2018 . A61K 36 /53 ( 2006 .01 ) Patent Cooperation Treaty , International Searching Authority , Writ ten Opinion for PCT/ US2018 /031538 , 7 pages , dated Sep . 17 , 2018 . A61P 31/ 14 ( 2006 .01 ) Perfect , M . et al ., “ Use of Complementary and Alternative Medicine (52 ) U . S . Cl. for the Treatment of Genital Herpes” , Herpes , Oct . 2005 , 12 ( 2 ) , pp . CPC . .. A61K 36 / 53 (2013 .01 ) ; A61P 31/ 14 38 -41 . ( 2018 .01 ) ; A61K 2236 /333 ( 2013 .01 ) Salvador, B . et al. , “ Filoviruses Utilize Glycosaminoglycans for (58 ) Field of Classification Search Their Attachment to Target Cells ” , Journal of Virology , Mar . 2013 None ( published ahead of print Jan . 2013 ) , 87 ( 6 ) , pp . 3295 - 3304 . USPTO , Non - Final Office Action for U . S . Appl. No. 14 / 443 ,767 , See application file for complete search history. dated Aug . 1 , 2018 , 8 pages . Wang , Z . et al ., “ High Genetic Diversity in Sarracenia leucophyl (56 ) References Cited la (Sarraceniaceae ) , a Carnivorous Wetland Herb ” , Journal of Hered U . S . PATENT DOCUMENTS ity , May 2004 , 95 ( 3 ) , pp . 234 - 243 . 2005 / 0095260 A1 5 / 2005 Pardoe * cited by examiner 2007 / 0122492 AL 5 / 2007 Behr et al. 2012 / 0141610 A1 6 / 2012 Gowey Primary Examiner — Michael Barker 2018 /0200320 A17 /2018 Langland et al. (74 ) Attorney , Agent, or Firm — Byrne Poh LLP ; Nina R . FOREIGN PATENT DOCUMENTS Horan EP 0249165 A2 12 / 1987 (57 ) ABSTRACT wo 2005074947 A2 8 / 2005 WO 2009048595 A2 4 / 2009 The present disclosure relates to methods of using Melissa WO 2014081976 A1 5 / 2014 officinalis extracts in inhibiting viral replication of a filovirus WO 2016012913 A1 1 / 2016 and in treating or preventing a filovirus infection . WO 2016123223 AL 8 / 2016 WO 2018208739 AL 11 /2018 19 Claims, 8 Drawing Sheets atent May 21, 2019 Sheet 1 of 8 ?? 10, 293 ,012 B2 Melissa extractmlul/18 23 : ? ?????) : ????????? ?????? 8:26???? : ???: : : : : : * ?? : : ?? - ?? ,??? ? 22:30 3 : ?????? ?????? . 8?????????: ??? ?????? ????????: : : ???? 2018 ? , ???9 ???????? ? : ???????????? ?????????? ??? 2ul/ml ??/Ino / ?? ? ???????????????? ? snJIA ON HSV1 FIG.1 atent May 21 , 2019 Sheet 2 of 8 US 10 ,293 ,012 B2 ul/mlMelissa HSVIbindingtoheparinagarose:Melissacompetition 3 . 0 FIG.2 atent May 21 , 2019 Sheet 3 of 8 US 10 ,293 ,012 B2 S[120+essija LASH+essilew- ovethe .- .- .- . -. .- .- .- .- .- .- . -. .-, - . -. .- .A (?????????????in?soa IMA -. formation plaque Percent EOH U . S . Patent May 21, 2019 Sheet 4 of 8 US 10 ,293 ,012 B2 -Melissa(gBbindingdeleted) -Melissa(gDbindingdepleted) mempenMelissa iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii 3 2.5 2 1.5Dose(ul/ml) 1 50. 120 100 formation plaque Percent FIG.4 U . S . Patent May 21 , 2019 Sheet 5 of 8 US 10 ,293 ,012 B2 Cellviability(vehicle) -+Cellviability(botanical) wwwVirusinhibition Selectivityindex:327 miul/58.ECso:0 CCgQ:190ul/mi 1000 C 100 10 Dose(ulextract/mlmedia) 0.1 120 formation plaque Percent FIG.5 U . S . Patent May 21, 2019 Sheet 6 of 8 US 10 ,293 ,012 B2 10 SV40 Adeno*Reo VACV YYYYYYYY media)mlextract/ulDose( EMCV HSV-1selfsVSV Melissaofficinalis HSV-2w ** Ebola-VSV 6.FIG formation plaquePercent atent May 21 , 2019 Sheet 7 of 8 US 10 ,293 ,012 B2 ASAodborar ' gooooooooooooWood' DooOOOOOOOOOOOOOOO waHSV-1 ' CodexoxOOKOOKOO Dose(ulextract/mlmedia) 2-ASH Melissaofficinalis VSVEbola- w Voor FIG.7 formation plaque Percent atent May 21 , 2019 Sheet 8 of 8 US 10 ,293 ,012 B2 16 14 12 10 Dose(ulextract/mlmedia) 8 VSV 6 Lavandulaofficinalis 4 VSVEbola- 2 ???????????????? ? ? ? ? ?? FIG.8B formation plaque Percent VSV Dose(ulextract/mlmedia) Hypericumperforatum VSVEbola-www FIG.8A . WWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWWW formation plaque Percent US 10 , 293 , 012 B2 METHODS OF USING EXTRACTS OF raphy . After removal of g? binding components present in MELISSA OFFICINALIS AGAINST the Melissa extract , the HSV1 inhibitory activity was greatly FILOVIRUSES reduced ( FIG . 4 ). This result suggests that the active con stituent of Melissa binds to g? of the virion particle . In BACKGROUND 5 summary , these results support that Melissa extracts inhibit herpes virus binding to heparin sulfate on the cell surface by Medicinal plant extracts are of interest as sources of novel binding to the HSV1 g? and blocking viral attachment. antiviral agents . Melissa officinalis , commonly known as Cell cytotoxicity is an important concern when consider Lemon Balm , is an abundant botanical historically claimed ing any potential therapeutic . In assays , inhibition of HSV1 ave strong antiviral properties. Melissa has a long 10 virus replication occurred at a low dose ( EC50 = 0 .58 ul /ml ) medicinal history being used first up to two thousand years (FIG . 5 ) . Upon testing for cell cytotoxicity , the extract did ago by the Greeks . Melissa is purported to help significantly not exhibit detectable cell cytotoxicity with the CC = 0 = 190 in the treatment of herpes simplex viruses, HSV1 and HSV2. The antiviral activity associated with Melissa has utilized ul/ ml being comparable to glycerin ( vehicle ) alone. (FIG . 5 ) . glycerine -based extracts prepared from dried Melissa offi - 15 SUMMARY cinalis . The botanical was ground to a fine powder followed by resuspension in 75 % glycerin (pharmaceutical grade , The present disclosure relates to the discovery that organic vegetable glycerin ) at a ratio of 1 : 8 ( dried plant extracts of the botanical Melissa officinalis have antiviral material to extraction solution ). The solution was stored at activity against filoviruses . Accordingly , the present disclo room temperature for seven days followed by removal of the 20 sure provides a method of using Melissa officinalis extracts botanical debris by centrifugation and sterilization through a in inhibiting viral replication of a filovirus . The present 0 . 2 um filter . disclosure also provides a method of using Melissa offici Previous studies have demonstrated that extracts from nalis extracts in treating or preventing a filovirus infection . Melissa officinalis can inhibit the replication of herpes In one embodiment, the filovirus is an Ebola virus . In viruses . As shown in FIG . 1 ( lower left corner ), cells 25 another embodiment , the filovirus is Marburg virus. infected with HSV lead to dramatic cytopathic effects and cell death . As cells were treated with increasing concentra BRIEF DESCRIPTION OF THE FIGURES tions of Melissa extract , a dose dependent reduction in cell death was observed . Uninfected